SECTOR
Piramal Pharma’s arm inks pacts to acquire ‘Kenalog’ from BMS
Jan-29-2026

Piramal Pharma’s step-down wholly owned subsidiary -- Piramal Critical Care B.V. has entered into definitive agreements for acquisition of ‘Kenalog’ and its associated brands from Bristol-Myers Squibb Company (BMS) for an upfront consideration of $35 million, and contingent consideration up to an amount not exceeding $65 million, payable on agreed operational and financial milestones. The transaction closing is subject to the fulfilment of certain substantive closing conditions.

Kenalog, a branded commercial injectable product containing Triamcinolone Acetonide, is a synthetic corticosteroid with anti-inflammatory, antipruritic & antiallergic action and is indicated as an adjunctive therapy in acute gouty arthritis, rheumatoid arthritis, and other conditions to treat inflammation. It is currently marketed by BMS across 15 countries under multiple trademarks such as Kenalog, Kenacort, Trigon, and Adcortyl. The said acquisition is expected to further leverage the company’s extensive distribution network spanning across 6,000 plus hospitals in more than 100 countries and is also expected to help broaden the CHG product portfolio, adding a new lever of growth for the future, especially in US, Europe & Asia pacific.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

  RELATED NEWS >>